Ensemble Therapeutics, Novartis deal

Ensemble granted Novartis exclusive, worldwide rights to its lead program of small molecule macrocyclic antagonists of IL-17A

Read the full 175 word article

How to gain access

Continue reading with a
two-week free trial.